Profile data is unavailable for this security.
About the company
Cipla Limited is an India-based company, which is primarily engaged in the business of pharmaceuticals. The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. The Company's product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The Company's geographical segments include India, the United States, South Africa, and Rest of the World. The Company has its network of manufacturing, trading and other incidental operations in India and International markets. The Company has approximately 47 manufacturing sites.
- Revenue in INR (TTM)257.74bn
- Net income in INR41.22bn
- Incorporated1935
- Employees26.62k
- LocationCipla LtdMumbai CentralMUMBAI 400013IndiaIND
- Phone+91 2 224826000
- Fax+91 2 224826120
- Websitehttps://www.cipla.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott India Ltd | 58.49bn | 12.01bn | 611.89bn | 3.81k | 50.94 | 16.54 | 48.09 | 10.46 | 565.30 | 565.30 | 2,752.52 | 1,740.71 | 1.20 | 4.96 | 17.09 | 15,335,370.00 | 24.64 | 20.92 | 33.37 | 28.59 | 44.94 | 44.20 | 20.54 | 17.26 | 1.94 | 111.00 | 0.022 | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
| Alkem Laboratories Ltd | 126.68bn | 17.96bn | 630.44bn | 16.87k | 35.11 | 6.11 | 29.87 | 4.98 | 150.19 | 150.19 | 1,059.44 | 862.57 | 0.8638 | 1.87 | 5.78 | -- | 12.35 | 11.88 | 17.39 | 17.50 | 61.02 | 59.43 | 14.30 | 13.94 | 1.94 | 8.32 | 0.1169 | 25.80 | 9.21 | 11.48 | 82.47 | 18.75 | -13.30 | 20.11 |
| Aurobindo Pharma Ltd | 290.02bn | 31.73bn | 783.05bn | 15.69k | 24.69 | 2.62 | 16.69 | 2.70 | 54.12 | 54.12 | 494.54 | 509.35 | 0.6827 | 1.38 | 6.25 | -- | 7.46 | 9.24 | 10.35 | 13.43 | 56.54 | 54.15 | 10.93 | 12.72 | 1.18 | 16.12 | 0.1821 | -- | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | -- |
| Lupin Ltd | 200.11bn | 19.14bn | 828.59bn | 20.79k | 43.39 | 5.79 | 28.27 | 4.14 | 41.88 | 41.88 | 437.77 | 313.60 | 0.8524 | 1.35 | 4.36 | 9,625,677.00 | 8.24 | 1.43 | 13.34 | 2.22 | 66.82 | 58.52 | 9.67 | 2.04 | 0.9702 | 9.18 | 0.1689 | 75.03 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Mankind Pharma Ltd | 103.35bn | 19.13bn | 856.90bn | 19.54k | 44.85 | 9.15 | 36.62 | 8.29 | 47.69 | 47.69 | 257.67 | 233.73 | -- | -- | -- | 5,289,035.00 | -- | -- | -- | -- | 68.94 | -- | 18.79 | -- | 2.35 | -- | 0.0212 | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Torrent Pharmaceuticals Ltd | 107.28bn | 16.56bn | 1.04tn | 14.92k | 62.49 | 15.10 | 42.22 | 9.65 | 48.94 | 48.94 | 316.97 | 202.58 | 0.7135 | 1.19 | 5.66 | 7,192,170.00 | 11.02 | 8.34 | 17.25 | 13.03 | 74.96 | 71.78 | 15.44 | 13.18 | 0.6142 | 7.24 | 0.3697 | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Dr Reddy's Laboratories Ltd | 280.11bn | 55.78bn | 1.11tn | 26.34k | 19.93 | 3.93 | 15.76 | 3.96 | 334.60 | 334.60 | 1,680.26 | 1,696.70 | 0.7874 | 1.46 | 3.67 | 10,633,220.00 | 15.68 | 11.37 | 21.05 | 16.02 | 70.69 | 65.86 | 19.91 | 14.63 | 1.92 | 41.28 | 0.0662 | 15.91 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Zydus Lifesciences Ltd | 195.47bn | 38.37bn | 1.19tn | 26.24k | 31.27 | 6.02 | 25.96 | 6.10 | 37.91 | 38.14 | 193.17 | 197.07 | 0.7103 | 1.74 | 4.05 | 7,449,467.00 | 13.92 | 9.05 | 19.29 | 14.01 | 68.14 | 61.15 | 19.60 | 14.33 | 1.48 | -- | 0.0351 | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Cipla Ltd | 257.74bn | 41.22bn | 1.22tn | 26.62k | 29.53 | 4.55 | 23.37 | 4.72 | 51.02 | 51.02 | 319.08 | 330.77 | 0.829 | 1.70 | 5.84 | -- | 13.37 | 10.09 | 16.16 | 12.40 | 65.78 | 59.69 | 16.12 | 12.66 | 2.71 | 58.30 | 0.0205 | 20.79 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Divi's Laboratories Ltd | 78.45bn | 16.00bn | 1.22tn | 17.50k | 76.08 | 8.97 | 61.53 | 15.51 | 60.26 | 60.26 | 295.51 | 511.21 | 0.5246 | 0.999 | 3.97 | 4,482,857.00 | 10.70 | 16.55 | 11.62 | 18.22 | 60.11 | 56.24 | 20.40 | 26.38 | 5.02 | -- | 0.0002 | 34.32 | 0.9976 | 9.66 | -12.25 | 3.41 | 6.47 | 13.40 |
Data as of Jul 22 2024. Currency figures normalised to Cipla Ltd's reporting currency: Indian Rupee INR
19.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 31 Mar 2024 | 29.57m | 3.66% |
| SBI Funds Management Ltd.as of 30 Jun 2024 | 26.18m | 3.24% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 19.87m | 2.46% |
| Norges Bank Investment Managementas of 31 Mar 2024 | 19.01m | 2.36% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2024 | 18.19m | 2.25% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 15.04m | 1.86% |
| ICICI Prudential Asset Management Co. Ltd.as of 30 Jun 2024 | 9.00m | 1.12% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 30 Jun 2024 | 8.23m | 1.02% |
| Kotak Mahindra Asset Management Co. Ltd.as of 30 Jun 2024 | 8.16m | 1.01% |
| DSP Asset Managers Pvt. Ltd.as of 30 Jun 2024 | 6.93m | 0.86% |
More ▼
Data from 31 Dec 2023 - 15 Jul 2024Source: FactSet Research Systems Inc.
